Cardiovascular Side Effects of Capecitabine
Primary Cardiovascular Manifestations
- The American College of Cardiology notes that capecitabine causes cardiovascular toxicity in approximately 3-9% of patients, with myocardial ischemia, arrhythmias, and coronary vasospasm being the primary manifestations, and patients with pre-existing cardiac disease face substantially elevated risk 1
- Capecitabine induces symptomatic ischemic ECG changes in 5.2% of patients without prior coronary artery disease, with the incidence ranging from 3-9% across studies 1
- The mechanism involves coronary vasospasm as the primary pathophysiologic driver, with ECG changes documented in 68% of patients experiencing cardiac events 1, 2
- Cardiac biomarker elevations occur in only 43% of cases with ischemic ECG changes, meaning normal troponins do not exclude capecitabine cardiotoxicity 1
Cardiac Arrhythmias
- The European Society of Cardiology notes that capecitabine causes multiple arrhythmia types including atrial fibrillation, supraventricular tachycardia, ventricular arrhythmias, bradycardia, and conduction disturbances 3, 4
- Bradycardia and atrioventricular block are specifically listed as capecitabine-associated arrhythmias by the European Society of Cardiology 3
High-Risk Patient Populations
- Patients with prior coronary vasospasm should generally avoid capecitabine in favor of alternative regimens whenever oncologically feasible, as they face substantially elevated risk for recurrent life-threatening events 2, 7
- Prior mediastinal radiation accelerates drug-related coronary damage 1
Critical Management Principles
- The American College of Cardiology suggests that alternative regimens not containing fluoropyrimidines are preferred over rechallenge with capecitabine 2
- Serial ECGs during treatment are recommended by the American College of Cardiology 2
- Frequent vital signs monitoring during treatment cycles is recommended 8
Mortality Risk
- Overall mortality from capecitabine cardiotoxicity ranges from 2.2% to 13% across studies 1
- Sudden cardiac death has been reported, likely related to ischemia and coronary vasospasm 3
Common Clinical Pitfalls
- Do not assume normal coronary angiography excludes capecitabine cardiotoxicity, as endothelial injury and small vessel thrombosis may be undetectable by angiography 2